Tulika Seth

All India Institute of Medical Sciences

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Renu Saxena

All India Institute of Medical Sciences

Saumyaranjan Mallick

All India Institute of Medical Sciences

Sudha Sazawal

All India Institute of Medical Sciences

K Keerthana

All India Institute of Medical Sciences Bhopal

Vijayakumar Arumugam Ramamurthy

Sree Balaji Dental College and Hospital

Mukul Agarwal

All India Institute of Medical Sciences

T Velpandian

All India Institute of Medical Sciences

Deepam Pushpam

DR. B.R.A. Institute Rotary Cancer Hospital

Manoranjan Mahapatra

All India Institute of Medical Sciences

Suman Kumar

Army Hospital Research and Referral

Cooperative Institutions

All India Institute of Medical Sciences

All India Institute of Medical Sciences Raipur

All India Institute of Medical Sciences Bhopal

DR. B.R.A. Institute Rotary Cancer Hospital

Sir Ganga Ram Hospital

Jawaharlal Institute of Post Graduate Medical Education and Research

Tata Memorial Hospital

Vardhman Mahavir Medical College & Safdarjung Hospital

National Institute of Medical Statistics

Creative Commons

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Kinetics of Blast Clearance in Cerebrospinal Fluid (CSF) Detected on Flow Cytometric Immunophenotyping (FCM), but Negative By Cytopathology in Newly Diagnosed Acute Lymphoblastic Leukemia Patients

Blood (2024)

Tulika Seth K Keerthana Jasmita Dass Mukul Agarwal Deepam Pushpam

Immunophenotyping

Cytopathology

Acute lymphocytic leukemia

10.1182/blood-2024-210015

Cite

Citations (0)

Utility of the trough plasma imatinib level monitoring at two time points in patients with the chronic myeloid leukemia-chronic phase

Journal of Cancer Research and Therapeutics (2014)

Tulika Seth Sanjeev Sharma Suman Kumar Vijayakumar Arumugam Ramamurthy Pravas Mishra

Plasma imatinib levels vary widely in patients with the chronic myeloid leukemia-chronic phase, and studies have shown improved hematological, cytogenetic, and molecular responses in patients with the higher trough imatinib levels.We analyzed 50 consecutive patients with the chronic myeloid leukemia-chronic phase and performed plasma imatinib levels at 1 month and 12 months and correlated them with complete hematological response at 3 months and molecular response at 12 months, respectively.Trough plasma imatinib levels at 1 month correlated well with complete hematological response at 3 months (P = 0.007) and levels at 12 months correlated with molecular response at 12 months (P = 0.04). Compliance to imatinib also significantly correlated with imatinib levels at 1 month (P = 0.0008) and imatinib levels at 12 months (P = 0.0002).Plasma imatinib levels may be of benefit in patients not achieving desired response at defined time intervals. The plasma level monitoring also helps in the assessment of drug compliance.

Trough level

Imatinib Mesylate

Chronic myelogenous leukemia

10.4103/0973-1482.136583

Cite

Citations (8)